 |
12 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- | azacitidine / Generic mfg.
Journal: Protein-driven mechanism of multiorgan damage in COVID-19. (Pubmed Central) - Oct 28, 2020
After removal of drugs having undesirable drug-drug interactions we select 7 drugs and one natural product: apabetalone, romidepsin, silmitasertib, ozanezumab, procaine, azacitidine, amlexanox, volociximab, and ellagic acid, whose combinations can palliate the organs and systems found to be damaged by COVID-19. We found that at least 4 drugs are needed to treat all the multiorgan damages, for instance: the combination of romidepsin, silmitasertib, apabetalone and azacitidine.
- ozanezumab (GSK 1223249) / GSK
Trial primary completion date: Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Apr 18, 2015
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
We found that at least 4 drugs are needed to treat all the multiorgan damages, for instance: the combination of romidepsin, silmitasertib, apabetalone and azacitidine. Trial primary completion date: Nov 2012 --> Jan 2012
- |||| ozanezumab (GSK 1223249) / GSK
Trial completion: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Mar 11, 2015
P2, N=304, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Nov 2012 --> Jan 2012 Active, not recruiting --> Completed
- || ozanezumab (GSK 1223249) / GSK
Trial primary completion date: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Dec 5, 2014
P2, N=294, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Nov 2014
- ozanezumab (GSK 1223249) / GSK
Enrollment closed: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Jan 22, 2014
P2, N=294, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2015 --> Nov 2014 Recruiting --> Active, not recruiting
- ozanezumab (GSK 1223249) / GSK
Trial initiation date: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Oct 30, 2013
P2, N=294, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Initiation date: Oct 2010 --> Dec 2012
- | ozanezumab (GSK 1223249) / GSK
New P2 trial: Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Dec 18, 2012
P2, N=294, Active, not recruiting, Sponsor: GlaxoSmithKline
- ||||| ozanezumab (GSK 1223249) / GSK
New P2 trial: A Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis (ALS) (EUDRACT) - Nov 11, 2012
P2, N=294, Ongoing, Sponsor: GlaxoSmithKline Research and Development Limited
- ozanezumab (GSK 1223249) / GSK
Trial termination: Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - May 9, 2012
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
Initiation date: Oct 2010 --> Dec 2012 Recruiting --> Terminated
- ozanezumab (GSK 1223249) / GSK
Trial termination: NOGO-A in Multiple Sclerosis FTIH (clinicaltrials.gov) - May 9, 2012
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Terminated Completed --> Terminated
- ozanezumab (GSK 1223249) / GSK
Enrollment change: Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - May 9, 2012
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
Completed --> Terminated N=40 --> 3
- ||| ozanezumab (GSK 1223249) / GSK
Trial completion, IO biomarker: First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 13, 2011
P1, N=76, Completed, Sponsor: GlaxoSmithKline
N=40 --> 3 Active, not recruiting --> Completed
- ozanezumab (GSK 1223249) / GSK
New P1 trial: Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 15, 2011
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
- ozanezumab (GSK 1223249) / GSK
New P1 trial: NOGO-A in Multiple Sclerosis FTIH (clinicaltrials.gov) - Aug 25, 2011
P1, N=3, Terminated, Sponsor: GlaxoSmithKline